Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Carcinoma, Lobular 1Breast Neoplasms 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × Liquid Biopsy × Clear all
NCT06067503 2026-04-13

Biomarkers to Detect Endocrine Therapy Resistance

University of Wisconsin, Madison

Phase 2 Recruiting
8 enrolled
Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡